Our impact
Learn more about our key achievements and explore our impact stories.
Last updated 31 July 2025
Our impact
As Singapore’s national health technology assessment agency, our work supports patients, healthcare providers and policy makers in making better informed decisions around patient care, and to improve access to clinically proven and affordable treatments.
We regularly evaluate the impact of our work including monitoring the adoption rate, improvement of health literacy, and real-world outcomes of patients. We work with clinical experts and patients to derive insights and provide feedback to help us improve our processes.
Our evaluation framework (see image below) comprises logic models that connect our activities to the anticipated short, intermediate, and long-term outcomes supported by underlying assumptions and contextual factors. These outcomes are measured through surveys, website analytics, indicator frameworks, administrative and utilisation data as well as real-world studies.
We report the progress and results to instill transparency and demonstrate the rigour of our work, and how they have contributed to improving the health and care of the nation.
Key achievements
*Estimated annual number of patients who can benefit from the subsidised medicines and medical technologies evaluated by ACE during the first year of subsidy listing
Reports
Impact stories
Reviewing the impact of our work
ACE impact reports show how our guidances and work have contributed to improved patient outcomes and healthcare value in Singapore.
Latest Impact Report: Non-calcium-based phosphate binders
Around six people are diagnosed with kidney failure each day, a threefold increase from two decades ago. A serious complication that can occur in the later stages of chronic kidney disease is hyperphosphataemia, which can lead to life-threatening consequences including cardiovascular calcification, bone diseases and secondary hyperparathyroidism.
Typical first-line treatment for hyperphosphataemia utilises calcium-based phosphate binders, subsidised by the Ministry of Health, Singapore. In cases of poor control or intolerance to these binders, patients may be switched to non-calcium-based phosphate options, as an additional therapy or as a standalone treatment. This demonstrated a high clinical need to make subsidised non-calcium-based phosphate binders available, to drive appropriate care.
Read our report [PDF, 2.2 MB]
Published December 2024
Previous impact reports
P2Y12 Inhibitors [PDF, 2.2 MB]
Published: December 2024
Biosimilars [PDF, 2.2 MB]
Published: December 2024
COPD [PDF, 2.3 MB]
Published: July 2024
NOACs [PDF, 2.2 MB]
Published: December 2022
Hepatits C [PDF, 3.3 MB]
Published: September 2022
The resources on this page are correct at the time of publication. Please review the associated guidances for any updates.